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Abstract
Introduction: Mesenchymal stem cells (MSCs) represent a heterogeneous cell population that is promising for
regenerative medicine. The present study was designed to assess whether VCAM-1 can be used as a marker of
MSC subpopulation with superior angiogenic potential.
Methods: MSCs were isolated from placenta chorionic villi (CV). The VCAM-1+/− CV-MSCs population were separated
by Flow Cytometry and subjected to a comparative analysis for their angiogenic properties including angiogenic genes
expression, vasculo-angiogenic abilities on Matrigel in vitro and in vivo, angiogenic paracrine activities, cytokine array,
and therapeutic angiogenesis in vascular ischemic diseases.
Results: Angiogenic genes, including HGF, ANG, IL8, IL6, VEGF-A, TGFβ, MMP2 and bFGF, were up-regulated in
VCAM-1+CV-MSCs. Consistently, angiogenic cytokines especially HGF, IL8, angiogenin, angiopoitin-2, μPAR, CXCL1,
IL-1β, IL-1α, CSF2, CSF3, MCP-3, CTACK, and OPG were found to be significantly increased in VCAM-1+ CV-MSCs.
Moreover, VCAM-1+CV-MSCs showed remarkable vasculo-angiogenic abilities by angiogenesis analysis with Matrigel
in vitro and in vivo and the conditioned medium of VCAM-1+ CV-MSCs exerted markedly pro-proliferative and pro-
migratory effects on endothelial cells compared to VCAM-1−CV-MSCs. Finally, transplantation of VCAM-1+CV-MSCs into
the ischemic hind limb of BALB/c nude mice resulted in a significantly functional improvement in comparison with
VCAM-1−CV-MSCs transplantation.
Conclusions: VCAM-1+CV-MSCs possessed a favorable angiogenic paracrine activity and displayed therapeutic efficacy
on hindlimb ischemia. Our results suggested that VCAM-1+CV-MSCs may represent an important subpopulation of MSC
for efficient therapeutic angiogenesis.
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Introduction
Peripheral arterial disease (PAD), characterized by the
critical limb ischemia (CLI) with high morbidity and
mortality risks, is gradually becoming an urgent life-
threatening disease in our aging society. To date, the
main treatments for PAD are bypass grafting and end-
arterectomy. However, surgery has not always been
allowed [1]. Numerous studies have demonstrated that
mesenchymal stem cells (MSCs) derived from different tis-
sue sources exert therapeutic efficacy on ischemia [2–5].
Varieties of reports have highlighted the therapeutic angio-
genesis of MSCs by focusing on differentiation and para-
crine mechanisms [6]. Several angiogenic cytokines and
enzymes secreted by MSCs, including vascular endothelial
cell growth factor (VEGF)-A [7], hepatocyte growth factor
(HGF) [8], interleukin (IL)-8 [9], transforming growth fac-
tor beta (TGFβ) [10], matrix metalloproteinases (MMPs)
[11], and so forth, have been widely reported to initiate
angiogenesis. Based on their angiogenic properties, MSCs
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are attractive in various clinical trials [12]. However, MSCs
have been known to be heterogeneous [13, 14] and it
remains to be determined whether some MSC subpopula-
tions exert superior angiogenic activities and are more suit-
able for therapeutic angiogenesis.
Vascular cell adhesion molecule 1 (VCAM-1), also
known as CD106, is extensively expressed on endothelial
cells [15], and is also constitutively expressed on some
stromal cells, existing in a particular vascular niche [16].
VCAM-1 plays a critical role in early embryonic devel-
opment since VCAM-1-deficient mice often die early or
show multiple severe defects in placental development
[17]. In addition, soluble VCAM-1 (sVCAM-1) has shown
evidence of mediating angiogenesis in rat cornea [18] and
the sVCAM-1/α4 integrin pathway plays an important
role in inflammatory stimuli-induced angiogenesis [19].
Recent studies demonstrated that VCAM-1 overexpres-
sion was associated with tumor angiogenesis, such as gas-
tric carcinoma [20], breast cancer [21], and renal cancer
[22]. These studies suggest VCAM-1 may be involved in
angiogenesis.
We have previously isolated a VCAM-1+ MSC subpop-
ulation of placenta chorionic villi (CV) that displayed
unique immunomodulation capacity. VCAM-1+CV-
MSCs secreted not only inflammatory factors but also
angiogenic cytokines [23]. The aim of this work was to
assess the angiogenic potential of the VCAM-1+CV-
MSC subpopulation, and to explore its therapeutic appli-
cation in an animal model of vascular ischemic disease.
Methods
Cell isolation and culture
This study was approved by the Ethical Committee and
the Institutional Review Board of the Chinese Academy of
Medical Science and Peking Union Medical College,
Tianjin, China. All volunteers provided informed consent.
CV-MSCs were harvested and cultured as described previ-
ously [23]. The regular culture medium for CV-MSCs was
DF12 medium (Gibco, Grand Island, NY, USA), 10 % fetal
bovine serum (FBS), 10 ng/ml epidermal growth factor
(EGF; Peprotech, Rocky Hill, NJ, USA), 2 mM glutamine
(Sigma, St.Louis, MO, USA), 1 % nonessential amino acids
(Gibco), and 100 U/ml penicillin–streptomycin (Invitro-
gen, Carlsbad, CA, USA). Human umbilical vein endothe-
lial cells (HUVECs) were harvested by digesting umbilical
vein with 0.25 % trypsin (Gibco) for 15 minutes at 37 °C.
The HUVECs were then cultured in EGM2-MV (Lonza,
Walkersville, MD, USA).
Flow cytometry analysis
The phenotype of CV-MSCs was analyzed using the follow-
ing antibodies: phycoerythrin (PE)-conjugated CD105,
CD73, CD166, CD29, CD54, VCAM-1, CD14, CD144, and
CD133; and fluorescein isothiocyanate (FITC)-conjugated
CD90, CD45, HLA-ABC, HLA-DR, and CD31. PE or FITC
isotype-matched antibodies served as controls. Cells were
examined by LSRII flow cytometer (BD Bioscience, San
Jose, CA, USA ). For cell sorting, CV-MSCs were stained
with PE-anti VCAM-1 antibodies for 30 minutes on ice
before cell sorting using the BD FACS Aria III cell sorter
(BD Biosciences, San Jose, CA, USA). All of the antibodies
were purchased from BD Pharmingen (San Diego, CA,
USA), and the flow cytometry data were analyzed by
FlowJo 7.6 software (San Carlos, CA, USA).
RNA extraction, reverse transcription, and real-time PCR
Total RNA was extracted using the E.Z.N.A. Total RNA
Kit I (OMEGA, Norcross, GA, USA), and cDNA synthe-
sis was performed using the MLV RT kit (Invitrogen).
All of the procedures followed the manufacturer’s in-
structions. Real-time PCR was performed on an Applied
Bio system 7900 Real-Time PCR System (Foster City,
CA, USA), using a SYBR Green-based real-time detec-
tion method. Primers used are shown in Additional file
1: Table S1. Each sample was performed in triplicate.
Tubular network formation assay in vitro
Pairs of VCAM-1+CV-MSCs and VCAM-1−CV-MSCs
were seeded at 2 × 104 cells/well gently on a Matrigel-
coated (BD Biosciences, Bedford, MA, USA) 96-well
plate. Photographs were taken by Microscope (Olympus,
Melville, NY, USA) 12 hours later. Tube numbers in
each well were counted. Three pairs of VCAM-1+CV-
MSCs and VCAM-1−CV-MSCs were used, and each
sample was performed in triplicate.
Matrigel plug angiogenesis assay in vivo
Six-week-old nude male mice were purchased from the
Institute of Experimental Animal (Beijing, China). All of
the animal experiments followed the Peking Union
Medical College Animal Care and Use Committee
guidelines. VCAM-1+/−CV-MSCs or nonseparated (NS)
CV-MSCs (106 cells) were suspended in 400 μl Matrigel
and injected subcutaneously into the dorsal area of nude
mice. Matrigel supplement with phosphate-buffered sa-
line (PBS) served as the negative control. Each group
contained three to six mice. Three weeks later, Matrigel
implants were harvested, photographed, fixed, sliced,
and stained with hematoxylin and eosin (H & E; Sigma).
Vessel numbers were counted under the microscope.
Frozen slices stained with alpha-smooth muscle actin
(α-SMA; Invitrogen) and von Willebrand factor (vWF;
Abcam, Cambridge, MA, USA) were employed to de-
tect the neovascular structures in the Matrigel plug.
Photographs were taken at × 20 and × 60 objectives by
confocal microscopy (UltraView; Perkin-Elmer, Wal-
tham, Massachusetts, USA).
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Conditioned medium preparation and proliferation assay
Pairs of 106 VCAM-1+/−CV-MSCs were incubated in
EBM2 medium (Lonza) for 48 hours. Then their condi-
tioned mediums (CMs) were collected, centrifuged at
1800 rpm for 10 minutes to remove cell debris, filtered
through 0.2 μm filters (Pall Corporation, Ann Arbor, MI,
USA), and frozen at –80 °C. To determine the pro-
proliferative effect, VCAM-1+/−CV-MSCCM supple-
mented with 2 % FBS were used to culture HUVECs for
72 hours. EBM2 supplemented with 2 % FBS, and
EGM2-MV (endothelial cells commercial culture
medium; Lonza) served as the negative and positive
control, respectively. The Cell Counting Kit 8 (Dojindo,
Rockville, MD, USA) method was used to measure
HUVEC proliferation at 24, 48, and 72 hours. ΔOD450
indicated the final data after subtracting the back-
ground. Each sample was performed in quadruplicate.
Scratch wound healing assay
When endothelial cells reached confluence, a scratch
wound was generated across each well using a pipette
tip. After washing with PBS, pairs of CM supplemented
with 2 % FBS, EGM2-MV, or EBM2 + 2 % FBS were used
to culture endothelial cells for 18 hours. The cleared
area of each well was photographed under × 40 magnifi-
cation at 0 and 18 hours, and measured by ImageJ soft-
ware (NIH, USA). The percentage of area repopulation
was calculated by the following formula:
% of area repopulation ¼ 1 − clear area of 18 hoursð Þ
∕ clear area of 0 hoursð Þ
Three pairs of CM were used and each sample was
performed in triplicate.
Enzyme-linked immunosorbent assay
The VEGF concentration in CM of VCAM-1+CV-MSCs
and VCAM-1−CV-MSCs was measured using an enzyme-
linked immunosorbent assay (ELISA; Neobioscience Bio-
tech, Shenzhen, China). Each sample was measured in
triplicate.
Human cytokine antibody array
The human cytokine antibody array (AAH-CYT-G1000)
was performed following the manufacturer’s instructions
(RayBiotech, Norcross, GA, USA) to detect 120 cytokine
expressions in supernatants (SN) of VCAM-1+/−CV-
MSCs. Cytokine signals above 200 were further studied,
and the cytokine signal ratio in VCAM-1+CV-MSCs and
VCAM-1−CV-MSCs was calculated. This was statisti-
cally significant if the cytokine signal ratio was >1.3 or
<0.75. Two pairs of VCAM-1+CV-MSCs and VCAM-1
−CV-MSCs were used. Each sample was performed in
duplicate. The targeted names of all cytokines involved
are presented in Additional file 1: Table S2.
Transplantation of VCAM-1+/−CV-MSCs in the hind limb
ischemia model
Nude mice (male, 7–8 weeks old, 18–22 g) were intraperi-
toneally anesthetized with 100 mg/kg sodium pentobarbital
(Sigma). Unilateral femoral artery ligation and excision
were performed as described previously [24]. Nude mice
were randomly divided into three groups (PBS, VCAM-
1+CV-MSCs, and VCAM-1−CV-MSCs groups) after ar-
terial ligations, and then 100 μl of a 106 cell suspension
or PBS was intramuscularly injected into ischemic hind
limbs within 6 hours post surgery. Blood perfusion in
ischemia and nonischemia limbs was measured by the
PeriCam PSI System (PERIMED AB Company, Järfälla,
stockholm, Sweden) on day 0, day 7, and day 20. Ische-
mia damage and functional assessment of ischemic
hind limbs in each treatment group were assessed on
day 20 according to the semiquantitative scores that
had been described previously [24].
Angiography
On day 20, after blood perfusion detection, mice were
sacrificed for angiography to evaluate the vessel density
in ischemic limbs. Angiographic images of hind limbs in
three treatments were acquired by the Kodak In-Vivo
FX ProImaging System (Kodak, New Haven, Connecti-
cut, USA), and the angiography score was employed [24]
to quantitatively analyze the collateral vessel formation
at the ischemia site.
Histological analysis
On day 20, after angiography, the ischemia adductor
muscle of nude mice in each group was collected, fixed
in 10 % formaldehyde (Sigma) overnight, and embedded
in paraffin. To detect capillary densities in ischemic sites,
H & E staining was performed and images were taken
under × 200 magnification. Vessels containing barium
sulfate or erythrocytes were counted, and the vessel
density in each group was calculated and compared.
Statistical analysis
Statistical analysis was performed using Graph Pad
Prism 6.0 (Graph Pad Software, Inc., San Diego, CA,
USA). All data are presented as mean ± standard error of
the mean. The Mann–Whitney test and one-way ana-
lysis of variance (ANOVA) were performed to determine
the significance. Fisher’s exact test (Freeman–Halton)
was employed to assess the outcome of transplantation
via a 3 × 3 contingency table. The difference was consid-
ered to be significant if p <0.05.
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Results
Characteristics of CV-MSCs
CV-MSCs expressed high levels of CD105 (98.21 % ±
1.28 %), CD73 (99.22 % ± 0.05 %), CD166 (71.72 % ±
13.23 %), CD29 (99.69 % ± 0.14 %), CD90 (97.94 % ±
1.91 %), HLA-ABC (94.32 % ± 2.09 %), CD54
(80.87 % ± 8.25 %), and VCAM-1 (62.9 % ± 5.36 %),
but hardly expressed endothelial cells markers (CD144,
CD133, and CD31), the hematopoietic cell markers (CD14
and CD45), and immunogenic marker HLA-DR. FACS
analysis of a representative sample is shown in Fig. 1a.
Phenotypes of CV-MSCs derived from three distinct do-
nors are presented in Additional file 1: Table S3. Cell sort-
ing was carried out to separate the VCAM-1+CV-MSCs
and VCAM-1−CV-MSCs (Fig. 1b), and the purity of cell
sorting was greater than 90 %. VCAM-1+CV-MSCs and
VCAM-1−CV-MSCs cultured in a flask showed typical
spindle fibroblast-like shapes; no morphological difference
was observed. Photographs of VCAM-1+CV-MSCs and
VCAM-1−CV-MSCs are presented in Fig. 1c (scale bar =
200 μm).
Angiogenic genes were highly expressed in VCAM-1+
CV-MSCs
Our previous gene profile result indicated that
VCAM-1+CV-MSCs expressed higher levels of angio-
genic cytokines than VCAM-1−CV-MSCs, such as IL-
6 (2.44-fold) and IL-8 (11.10-fold) [23]. Apart from
that, the CXC chemokine family (chemokine (C-X-C
motif ) ligand (CXCL)1–CXCL3, CXCL5, and CXCL6
and chemokine (C-C motif ) ligand (CCL7)), MMPs
(including MMP1 and MMP2), several growth factors
(VEGFA, HGF, basic fibroblast growth factor (bFGF),
TGFβ1, and TGFβ3), hypoxia-induced factor (HIF1A),
and angiopoietin-like protein 2 (ANGPTL2) were also
highly expressed in VCAM-1+CV-MSCs. Meanwhile, the
expressions of lymph-angiogenesis related VEGF-C and
intercellular cell adhesion molecule-1 (ICAM-1) were
lower in VCAM-1+CV-MSCs (Fig. 2a). Several critical an-
giogenic genes were further confirmed by real-time PCR.
Results showed that HGF, angiogenin (ANG), MMP2,
VEGFA, TGFβ, and bFGF expressed in VCAM-1+CV-
MSCs were upregulated to varying degrees, with a 3.34-
fold, 2.64-fold, 2.34-fold, 1.93-fold, 1.74-fold, and 1.14-fold
increase compared with VCAM-1−CV-MSCs, respectively
(n = 3–5; Fig. 2b).
VCAM-1+CV-MSCs displayed angiogenic potential on
Matrigel assay in vitro and in vivo
To determine the angiogenic potential of VCAM-1+CV-
MSCs and VCAM-1−CV-MSCs, a tubular network assay
was performed in vitro. To our surprise, without exogen-
ous VEGF, VCAM-1+CV-MSCs spontaneously formed
about 4.14-fold intact tubular structures on Matrigel com-
pared with VCAM-1−CV-MSCs (n = 3, p <0.01; Fig. 3a).
Matrigel plug angiogenesis assays in vivo [25] were then
performed to explore the angiogenic differences. Interest-
ingly, plenty of macroscopic blood vessels were observed
in the Matrigel plugs of the VCAM-1+CV-MSCs and NS
CV-MSCs groups rather than the VCAM-1−CV-MSCs
and PBS groups (Fig. 3b–i). H & E staining revealed that
the new outgrowth contained erythrocytes and the smooth
muscle layer (Fig. 3b ii, iii). Moreover, vessel densities in
the VCAM-1+CV-MSCs and NS CV-MSCs groups were
significantly higher than in the VCAM-1−CV-MSCs and
PBS groups (10.66 ± 0.67 and 11.84 ± 1.23 per mm2 vs.
0.36 ± 0.24 and 0.27 ± 0.19 per mm2,n = 3, p <0.0001;
Fig. 3c). However, the vessel density in the VCAM-1+CV-
MSCs and NS CV-MSCs groups was similar (p >0.05).
Besides that, a larger vessel lumen was observed in the
VCAM-1+CV-MSCs group rather than in the NS CV-
MSCs group, which could be related to a higher
VCAM-1+CV-MSC proportion in the transplanted
cells. Moreover, immunostaining of vWF and α-SMA
revealed that the fresh blood vessels contained endo-
thelial cells (labeled with anti-vWF antibodies) and
smooth muscle cells (labeled with anti-α-SMA anti-
bodies; Fig. 3d), indicating that the vessel structures
were intact and mature.
VCAM-1+CV-MSCCM effectively promoted endothelial cell
proliferation and migration
To explore the paracrine activities of VCAM-1+CV-
MSCs and VCAM-1−CV-MSCs, we collected their
CMs and performed endothelial cell proliferation and
scratch wound healing assay. Our data revealed that
compared with the VCAM-1−CV-MSCCM, VCAM-1
+CV-MSCCM significantly promoted endothelial cell
proliferation during 48 hours (n = 3, p <0.01), with the
most significant point at 24 hours (n = 3, p <0.001).
But this pro-proliferative effect was not significant
after 72 hours (n = 3, p >0.05; Fig. 4a). The reason for
this might be the exhaustion of angiogenic cytokines.
In addition, scratch assay that mimicked the wound
healing process in vitro was used to evaluate the pro-
migratory effects. After incubation for 18 hours, we sur-
prisingly found that endothelial cells cultured in VCAM-1
+CV-MSCCM reached confluence again. Representative
photographs were taken under × 40 magnification and the
percentage of area repopulation was calculated by Image
J software (NIH, USA) (Fig. 4b). VCAM-1+CV-MSCCM
significantly increased the cleared area recovery compared
with VCAM-1−CV-MSCCM (80.58 ± 6.88 vs. 56.36 ± 4.23,
n = 3, p <0.01; Fig. 4c), indicating that VCAM-1+CV-
MSCCM was richer in pro-migratory cytokines than
VCAM-1−CV-MSCCM. To figure out the paracrine mech-
anism of VCAM-1+CV-MSCs, we performed VEGF and
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Fig. 1 Phenotype of CV-MSCs and flow cell sorting. a Surface markers of CV-MSCs were evaluated by FACS analysis. CV-MSCs positively expressed
CD105, CD73, CD166, CD29, CD90, HLA-ABC, CD54, and VCAM-1, and hardly expressed CD14, CD45, CD31, CD144, CD133 and HLA-DR. A representative
sample is shown. b VCAM-1+CV-MSCs and VACM-1−CV-MSCs were separated by the BD Aria III cell sorting system. c Morphology of VCAM-1+CV-MSCs
and VCAM-1−CV-MSCs (scale bar = 200 μm). CV chorionic villi, MSC mesenchymal stem cell, SSC side scatter, VCAM-1 vascular cell adhesion molecule 1
Fig. 2 Angiogenic genes were upregulated in VCAM-1+CV-MSCs. a Gene expression profile of VCAM-1+CV-MSCs and VCAM-1−CV-MSCs determined
using Affymetrix oligoarray, with the angiogenic genes valued and expressed in log10. b Several raised angiogenic genes in VCAM-1
+CV-MSCs were
confirmed by real-time PCR, including IL-6, IL-8 [23], HGF, ANG, MMP2, VEGF-A, TGFβ, and bFGF (n = 3–5). ANG angiogenin, ANGPT2 angiopoietin-2,
ANGPTL2 angiopoietin-like protein 2, BFGF basic fibroblast growth factor, CCL Chemokine (C-C motif) ligand, CV chorionic villi, CXCL chemokine (C-X-C
motif) ligand, EGF epidermal growth factor, HGF hepatocyte growth factor, HIF hypoxia-induced factor, IL interleukin, MMP matrix metalloproteinase,
MSC mesenchymal stem cell, TGF transforming growth factor, VCAM-1 vascular cell adhesion molecule 1, VEGF vascular endothelial cell growth factor
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sVCAM-1 ELISAs. Results showed that the VEGF concen-
tration in VCAM-1+CV-MSCCM was 200 pg/ml, 3.6-fold
higher than VCAM-1−CV-MSCCM (n = 4, p <0.0001;
Fig. 4d), while the sVCAM-1 concentration was <20 pg/
ml (Additional file 1: Figure. S1). The fact that VEGF can
induce endothelial cell proliferation and migration [7]
may partially explain the pro-proliferative and pro-
migratory differences between VCAM-1+CV-MSCCM and
VCAM-1−CV-MSCCM on endothelial cells.
Cytokine antibody array revealed the angiogenic
secretome of VCAM-1+CV-MSCs
To systematically study the secretome of VCAM-1+CV-
MSCs and VCAM-1−CV-MSCs, we performed the hu-
man cytokine antibody array (AAH-CYT-G1000). Our
data revealed that: the differential cytokines from the
two donors were similar between VCAM-1+CV-MSCs
and VCAM-1−CV-MSCs (Fig. 5a); the VCAM-1+CV-
MSC secretome contained a significantly higher level of
angiogenic cytokines (Fig. 5b, Additional file 1: Table S4),
including IL-1β (6.57-fold), hematopoietic colony-
stimulating factor 2 (CSF2)/granulocyte–macrophage
colony-stimulating factor (GM-CSF, 5.73-fold), CSF3/
granulocyte colony-stimulating factor (G-CSF; 2.03-fold),
IL-8 (1.70-fold), CXCL1 (Growth regulated oncogene-α
(GRO-α), 1.48-fold), osteoprotegerin (OPG, 1.46-fold),
urokinase-type plasminogen activator receptor (μPAR,
1.69-fold), IL-1α (1.6-fold), angiopoietin-2 (ANGPT2,
1.35-fold), HGF (1.33-fold), ANG (1.33-fold), monocyte
chemotactic protein-3 (MCP-3/CCL-7, 1.31-fold), and
cutaneous T-cell attracting chemokine (CTACK/
CCL27, 1.30-fold), some of those differential cytokines
consistent with our gene profile results; and the secre-
tion of RANTES (0.68-fold) and TARC (0.74-fold) was
lower in VCAM-1+CV-MSCs than in VCAM-1–CV-
MSCs (Fig. 5b). Because of a signal value less than 200,
VEGF was not the principal cytokine secreted by CV-
MSCs in normal conditions.
VCAM-1+CV-MSCs exerted therapeutic efficacy on hind
limb ischemia
To investigate the therapeutic neovascularization of
VCAM-1+CV-MSCs, we constructed a vascular ische-
mia animal model and intramuscularly injected 106
VCAM-1+/−CV-MSCs into the ischemic limbs within
6 hours post surgery. PBS served as a negative control.
To estimate the therapeutic effect, we classified mice into
three outcomes: limb salvage, foot necrosis, and limb loss.
Different percentage distributions of outcomes among
three groups were calculated and Fisher’s exact test
(Freeman–Halton) was used to analyze this result (p =
0.10, n = 11; Fig. 6a). From the data, mice in the PBS
group suffered the maximal amputation rate (54.5 %)
and foot necrosis rate (27 %). The amputation rate in
the VCAM-1−CV-MSCs group was much higher than
in the VCAM-1+CV-MSCs group (36.4 % vs. 9 %),
while the foot necrosis rate in both of them was 18.2 %.
Semiquantitative scores of ischemia damage and
Fig. 3 VCAM-1+CV-MSCs revealed vasculoangiogenic potential by angiogenesis analysis with Matrigel in vitro and vivo. a VCAM-1+CV-MSCs
spontaneously formed much more intact tube-structures on Matrigel than VCAM-1−CV-MSCs (n = 3, ** p <0.01), indicating that VCAM-1+CV-
MSCs possessed vasculogenic potential. Representative images are shown (scale bar = 500 μm). Each sample was performed in triplicate. b Macroscopic
and microscopic view of Matrigel plugs. The Matrigel plug was harvested 21 days later; macroscopic vessels were seen in the Matrigel plug in the VCAM-
1+CV-MSCs and NS CV-MSCs groups i. H & E staining was performed to reveal the vessel density in Matrigel plug (scale bar: ii= 500 μm; iii= 200 μm).
c Vessel densities in the VCAM-1+CV-MSCs and NS CV-MSCs groups were much greater than in the PBS and VCAM-1−CV-MSCs groups (n= 3, **** p
<0.0001). d New outgrowth in Matrigel plug was immunostained with vWF and α-SMA antibodies to indicate the endothelial cells and smooth
muscle cells, respectively. Photographs were taken under × 20 (bottom) and × 60 (upper) magnifications. α-SMA alpha smooth muscle actin, CV
chorionic villi, DAPI 4',6-diamidino-2-phenylindole, MSC mesenchymal stem cell, NS nonseparated, PBS phosphate-buffered saline, VCAM-1 vascular cell
adhesion molecule 1, vWF von Willebrand factor
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ambulatory impairment were used to assess ischemic
states and physiological function of ischemic limbs. Re-
sults indicated that VCAM-1+CV-MSCs significantly
alleviated the ischemia damage and ambulatory impair-
ment (0.77 ± 0.37 and 0.59 ± 0.24), much better than
the PBS group (2.77 ± 0.52 and 1.82 ± 0.33, n = 11, p
<0.05), while VCAM-1−CV-MSCs showed a slight im-
provement compared with PBS treatment (1.86 ± 0.57
and 1.18 ± 0.36, n = 11, p >0.05; Fig. 6b, c).
In addition, blood perfusion detected by the PeriCam
PSI System was utilized to evaluate ischemia restoration
on days 0, 7 and 20 post surgery (Fig. 6d). The blood
perfusion ratio in ischemic and healthy limbs was cal-
culated and compared by ANOVA Bonferroni’s mul-
tiple test. Data showed a significant blood flow
increased on day 7 and day 20 post surgery in the
VCAM-1+CV-MSCs group (0.79 ± 0.07 and 0.92 ±
0.07), much higher than the VCAM-1−CV-MSCs group
(0.48 ± 0.08 and 0.65 ± 0.08, n = 11, *p <0.05) and the
PBS group (0.50 ± 0.07 and 0.57 ± 0.07, n = 11, *p <0.05,
**p <0.01; Fig. 6e). By comparison, VCAM-1−CV-MSCs
did not show similar therapeutic effects as VCAM-1
+CV-MSCs (p >0.05; Fig. 6e). To study collateral vessel
development at the ischemic site, mice underwent angi-
ography and in vivo images on day 20 post surgery.
Representative photographs are shown in Fig. 6f. The
angiography score that described vessel density was
used to analyze the neovascularization. Results demon-
strated that VCAM-1+CV-MSCs significantly augmented
the generation of collateral vessels at the ischemia site
(n = 3–5, *p <0.05; Fig. 6g), whose angiography score
was 1.52-fold and 1.28-fold higher than the PBS and
VCAM-1−CV-MSCs groups, respectively. H & E stain-
ing further confirmed that the vessel density in the
VCAM-1+CV-MSCs group was 6.3-fold and 2.17-fold
more than the PBS and VCAM-1−CV-MSCs groups (n = 7,
*p <0.05, ***p <0.001, ****p <0.0001; Fig. 6h, i).
Discussion
Previous studies have reported that MSCs displayed
remarkable therapeutic properties on vascular ischemic
diseases such as myocardial infarction, stroke, and perivas-
cular ischemic diseases [12]. However, the mechanisms of
therapeutic angiogenesis induced by MSCs have not yet
been well defined. Several investigators have proposed that
paracrine factors secreted from MSCs, including a core of
Fig. 4 VCAM-1+CV-MSCCM exerted angiogenic paracrine effects on endothelial cells. a Endothelial cell proliferation assay was used to study the
pro-proliferative activity of VCAM-1+CV-MSCs and VCAM-1−CV-MSCs. By comparison with VCAM-1−CV-MSCCM, VCAM-1+CV-MSCCM significantly
promoted endothelial cell proliferation during 48 hours, but this effect was not significant at 72 hours (n = 3, **p <0.01, ***p <0.001). Each sample
was done in quadruplicate. b Wound healing assay was performed to study the pro-migratory effect of VCAM-1+/−CV-MSCs. Representative photographs
were shown at 0 and 18 hours under × 40 magnification. c Result of area repopulation (%) indicating that VCAM-1+CV-MSCCM efficiently accelerated the
endothelial cell wound healing process compared with VCAM-1−CV-MSCCM (n= 3, **p <0.01). Each sample was performed in triplicate. d VEGF concentra-
tion in VCAM-1+CV-MSCCM and VCAM-1−CV-MSCCM measured by ELISA (n= 4, ****p <0.0001). Each sample was tested in triplicate. CM conditioned
medium, CV chorionic villi, MSC mesenchymal stem cell, VCAM-1 vascular cell adhesion molecule 1, VEGF vascular endothelial cell growth factor
Du et al. Stem Cell Research & Therapy  (2016) 7:49 Page 8 of 13
angiogenic cytokines (i.e., VEGF, HGF, IL-8, TGFβ), exo-
somes [26], and microvesicles [27], might be the major
contributors [28]. Gnecchi et al. [29] reported that injec-
tion with the CM of Akt-modified MSCs abundant with
VEGF, bFGF, HGF, and TB4 significantly improved cardiac
performance after induced myocardial infarction. Recent
studies using cell labeling [30] and single cell technology
[31] also supported the major status of paracrine action in
MSC-mediated angiogenesis.
In this study, we have firstly demonstrated that the
VCAM-1+CV-MSC subpopulation displayed a potent
angiogenic property and exerted enhanced therapeutic
efficacy on regeneration after ischemia in comparison
with the VCAM-1−CV-MSC subpopulation.
We then wanted to know why VCAM-1+CV-MSCs pos-
sessed superior pro-angiogenic activities than VCAM-1
−CV-MSCs. We were interested to note a superior angio-
genic secretome from VCAM-1+CV-MSCs, including
HGF, IL-8, ANG, ANGPT2, CXCL1/GRO-α, μPAR, IL-1β,
IL-1α, CSF2/GM-CSF, CSF3/G-CSF, MCP-3, CTACK/
CCL27, and OPG. Previous studies have shown that HGF
potently stimulated endothelial cell motility and growth
[32]. IL-8 promoted angiogenesis via directly enhancing
endothelial cell proliferation, survival, and MMP produc-
tion [33]. ANG potently induced new blood vessel forma-
tion [34]. ANGPT-2 potentiated the effects of other
angiogenic cytokines in vivo and initiated neovasculariza-
tion [35]. CXCL1 enhanced microvascular endothelial cell
Fig. 5 Human cytokine antibody array displayed the angiogenic secretome of VCAM-1+CV-MSCs. a Expression of 120 cytokines in SN of VCAM-1+CV-
MSCs and VCAM-1−CV-MSCs was determined by human cytokine antibody array (AAH-CYT-G1000). VCAM-1+CV-MSC and VCAM-1−CV-MSC SN derived
from two healthy donors were used. Each sample was performed in duplicate. The differential angiogenic cytokines between VCAM-1+CV-MSCs and
VCAM-1–CV-MSCs were similar in two healthy donors. b Cytokine signal >200 was analyzed, and ratio of cytokine signal in VCAM-1+CV-MSCs to VCAM-
1−CV-MSCs was calculated. This was statistically significant if the cytokine signal ratio was >1.3 or <0.75. Data revealed that VCAM-1+CV-MSCs secreted
more abundant angiogenic cytokines than VCAM-1–CV-MSCs, including HGF, IL-8, ANG, ANGPT2, μPAR, CXCL1, IL-1β, IL-1α, CSF2, CSF3, MCP-3, CTACK,
and OPG. CV chorionic villi, MSC mesenchymal stem cell, VCAM-1 vascular cell adhesion molecule 1. See Abbreviations for cytokine definitions
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Du et al. Stem Cell Research & Therapy  (2016) 7:49 Page 10 of 13
migration and tube formation [36]. μPAR induced
endothelial cell invasion and proliferation in the initial
period of angiogenesis [37]. IL-1β [38], IL-1α [39], GM-
CSF [40], and G-CSF [41] were reported to initiate
angiogenesis by stimulating VEGF production or acti-
vating the angiogenesis-related pathway. MCP-3 stimu-
lated the migration of circulating angiogenic cells and
angiogenesis partially via the chemokine (C-X-C motif )
receptor 1 (CCR1) [42]. CTACK/CCL27 was reported
to accumulate the CD34+ bone marrow cells (express-
ing CCR10) to participate in skin wound healing and
repair [43]. OPG was a positive regulator of microvessel
formation in vivo and could activate endothelial colony-
forming cells [44]. In addition, we have performed the
endothelial cell differentiation assay in vitro and have not
found significant differences between VCAM-1+CV-MSCs
and VCAM-1−CV-MSCs (seen by immunostaining of
vWF) under a confocal microscope (Additional file 1: Fig-
ure. S2). Based on these studies, we believed that paracrine
action rather than differentiation was the principal mech-
anism of the therapeutic angiogenesis induced by MSCs.
Besides, the superior angiogenic effect of VCAM-1+CV-
MSCs could be a result of a synergic effect of multiple an-
giogenic factors secreted by cells.
To date, the identification of MSC still relies on the min-
imal criteria specified in 2006 (plastic adhesion, expressing
a set of membrane antigens and tridifferentiation capacities)
[45]. Besides these properties, the trait of MSCs varies
among different origins and individuals; that is, the para-
crine actions [46], and immunomodulatory [23] and
hematopoietic support capacities [47]. In addition, MSCs
isolated from the same tissue also comprised a heteroge-
neous population. A variety of markers (i.e., Stro-1, SSEA-4,
CD271, CD146) have hence been adopted to investigate the
potential of particular MSC subpopulations [14]. Psaltis et
al. [48] reported that stro-1+ bone marrow-derived MSCs
possessed unique cardiovascular paracrine activities. Inter-
estingly, Gronthos et al. [49] employed VCAM-1 as a coex-
pressed maker to enrich stro-1+ MSCs. Our data agree with
Psaltis et al.’s study, which verified the consistent angiogenic
potentials of VCAM-1+ MSCs. Most recently, Wang et al.
[50] reported that MSCs pretreated with IL-1β and tumor
necrosis factor alpha could enhance the therapeutic efficacy
on cardiovascular ischemia via upregulating VCAM-1 ex-
pression. Consistently, our study demonstrated the pres-
ence of a natural VCAM-1+ MSC subpopulation in vivo in
placenta CV that exerted excellent paracrine action. Add-
itionally, it has been shown that placenta CV and bone
marrow abundant with capillaries contained many more
VCAM-1+ MSCs (68 % and 13 %) than adipose tissue and
umbilical cord (0.24 % and 4 %) [23], suggesting that
VCAM-1+ MSCs might play important roles in the physio-
logical vasculogenesis and angiogenesis.
Conclusion
Our comparative studies at multiple levels on the angio-
genic properties of VCAM-1+CV-MSCs and VCAM-1–
CV-MSCs showed that VCAM-1 could be used as a sur-
face marker to select a MSC subpopulation with super-
ior pro-angiogenic activity. Moreover, the exciting
therapeutic efficacy of VCAM-1+CV-MSCs on ischemic
nude mice not only provided a novel strategy for cell-
based therapy of ischemic diseases, but also a hint for
banking appropriate MSCs for clinical usage.
Additional file
Additional file 1: is Table S1 presenting primers for real-time reverse
transcription PCR, Table S2 presenting the description of the human cytokine
antibody array (AAH-CYT-G1000), Table S3 presenting the phenotype of
three donor-derived CV-MSCs, Table S4 presenting differential angiogenesis
cytokines of VCAM-1–CV-MSCs and VCAM-1+CV-MSCs, Fig. S1 showing
sVCAM-1 concentration in 48-hour CM of VCAM-1+CV-MSCs and VCAM-1–
CV-MSCs measured by ELISA, and Fig. S2 showing the endothelial-like cells
derived from VCAM-1+CV-MSCs and VCAM-1–CV-MSCs harvested after in
vitro endothelial induction and immunostained by anti-vWF antibodies
to evaluate their endothelial differentiation capacities. (PDF 524 kb)
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Fig. 6 Transplantation of VCAM-1+CV-MSCs significantly enhanced the blood perfusion and the generation of collateral vessels in the ischemic
sites. a VCAM-1+/−CV-MSCs or PBS were injected into the ischemic site of nude mice. Percentage distributions of limb salvage, foot necrosis, and
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Du et al. Stem Cell Research & Therapy  (2016) 7:49 Page 11 of 13
CSF: Colony-stimulating factor; CTACK: Cutaneous T-cell attracting chemokine;
CV: Chorionic villi; CXCL: Chemokine (C-X-C motif) ligand; EGF: Epidermal
growth factor; ELISA: Enzyme-linked immunosorbent assay; FACS: Fluorescence-
activated cell sorting; FBS: Fetal bovine serum; FITC: Fluorescein isothiocyanate;
G-CSF: Granulocyte-colony stimulating factor; GM-CSF: Granulocyte–macrophage
colony-stimulating factor; GRO-α: Growth regulated oncogene-α; H &
E: Hematoxylin and eosin; HGF: Hepatocyte growth factor; HIF: Hypoxia-induced
factor; HUVEC: Human umbilical vein endothelial cell; ICAM-1: Intercellular cell
adhesion molecule-1; IL: Interleukin; MCP: Monocyte chemotactic protein;
MMP: Matrix metalloproteinase; MSC: Mesenchymal stem cell; NS: Nonseparated;
OPG: Osteoprotegerin; PAD: Peripheral arterial disease; PBS: Phosphate-buffered
saline; PE: Phycoerythrin; RANTES: Regulated on activation, normal T cell expressed
and secreted; SN: Supernatants; sVCAM-1: Soluble vascular cell adhesion molecule
1; TARC: Thymus and activation regulated chemokine; TGFβ: Transforming growth
factor beta; μPAR: Urokinase-type plasminogen activator receptor; VCAM-
1: Vascular cell adhesion molecule 1; VEGF: Vascular endothelial cell growth factor;
vWF: Von Willebrand factor.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
WD and Z-CH carried out the conception, designed the experiment, and drafted
the manuscript. WD, XL, YC, and SY isolated CV-MSCs, and performed FACS
analysis and cell sorting. Z-BH and ZY performed the Affymetrix oligoarrays. WD
and ZY carried out the real-time PCR. WD and SY performed the Matrigel
angiogenesis assay in vitro and in vivo. WD performed proliferation and the
scratch wound healing assay. Z-BH performed the cytokine array and analyzed
the data. WD, XL, YC, TM, BS, JC, LL, JL, FC, SL, and JT built the vascular ischemia
model, performed cell transplantation, evaluated the ischemia scores, detected
the blood perfusion, carried out the angiography, and performed the histological
staining. Z-CH, Z-BH, FM, ZL, and XF participated in data analysis and manuscript
writing. All authors revised their corresponding content and approved the final
manuscript.
Acknowledgements
This study was supported by The National Basic Research Program of China
(2011CB964802), The National Science and Technology Support Program
(2013BAI01B09), and The Natural Science Foundation of China (81330015
and 31470951).
Author details
1The State Key Laboratory of Experimental Hematology, Institute of
Hematology and Hospital of Blood Diseases, Chinese Academy of Medical
Sciences & Peking Union Medical College, No.288, Nanjing Road, Heping
District, Tianjin 300020, China. 2Beijing Institute of Health and Stem Cells,
No.1 Kangding Road, BDA, Beijing 100176, China. 3National Engineering
Research Center of Cell Products, No.80, Fourth Avenue, TEDA, Tianjin
300457, China.
Received: 29 October 2015 Revised: 16 January 2016
Accepted: 22 February 2016
References
1. Ouriel K. Peripheral arterial disease. Lancet. 2001;358(9289):1257–64.
doi:10.1016/S0140-6736(01)06351-6.
2. Kinnaird T, Stabile E, Burnett MS, Shou M, Lee CW, Barr S, et al. Local
delivery of marrow-derived stromal cells augments collateral perfusion
through paracrine mechanisms. Circulation. 2004;109(12):1543–9.
doi:10.1161/01.CIR.0000124062.31102.57.
3. Xu Y, Meng H, Li C, Hao M, Wang Y, Yu Z, et al. Umbilical cord-derived
mesenchymal stem cells isolated by a novel explantation technique can
differentiate into functional endothelial cells and promote revascularization.
Stem Cells Dev. 2010;19(10):1511–22. doi:10.1089/scd.2009.0321.
4. Kim SW, Zhang HZ, Kim CE, An HS, Kim JM, Kim MH. Amniotic
mesenchymal stem cells have robust angiogenic properties and are
effective in treating hindlimb ischaemia. Cardiovasc Res. 2012;93(3):525–34.
doi:10.1093/cvr/cvr328.
5. Hongyan Tao ZH, Zhong Chao Han, and Zongjin Li. Proangiogenic features
of mesenchymal stem cells and their therapeutic applications. Stem Cells
Int. 2016;2016:1314709. doi:10.1155/2016/1314709.
6. Wu Y, Chen L, Scott PG, Tredget EE. Mesenchymal stem cells enhance
wound healing through differentiation and angiogenesis. Stem Cells. 2007;
25(10):2648–59. doi:10.1634/stemcells.2007-0226.
7. Shizukuda Y, Tang S, Yokota R, Ware JA. Vascular endothelial growth factor-
induced endothelial cell migration and proliferation depend on a nitric oxide-
mediated decrease in protein kinase Cdelta activity. Circ Res. 1999;85(3):247–56.
8. Ding S, Merkulova-Rainon T, Han ZC, Tobelem G. HGF receptor up-
regulation contributes to the angiogenic phenotype of human endothelial
cells and promotes angiogenesis in vitro. Blood. 2003;101(12):4816–22.
doi:10.1182/blood-2002-06-1731.
9. Li A, Dubey S, Varney ML, Dave BJ, Singh RK. IL-8 directly enhanced
endothelial cell survival, proliferation, and matrix metalloproteinases
production and regulated angiogenesis. J Immunol. 2003;170(6):3369–76.
10. Mahmoud M, Upton PD, Arthur HM. Angiogenesis regulation by TGFbeta
signalling: clues from an inherited vascular disease. Biochem Soc Trans.
2011;39(6):1659–66. doi:10.1042/BST20110664.
11. Rundhaug JE. Matrix metalloproteinases and angiogenesis. J Cell Mol Med.
2005;9(2):267–85.
12. Salem HK, Thiemermann C. Mesenchymal stromal cells: current understanding
and clinical status. Stem Cells. 2010;28(3):585–96. doi:10.1002/stem.269.
13. Tolar J, Le Blanc K, Keating A, Blazar BR. Concise review: hitting the right
spot with mesenchymal stromal cells. Stem Cells. 2010;28(8):1446–55.
doi:10.1002/stem.459.
14. Lv FJ, Tuan RS, Cheung KM, Leung VY. Concise review: the surface markers
and identity of human mesenchymal stem cells. Stem Cells. 2014;32(6):
1408–19. doi:10.1002/stem.1681.
15. Rice GE, Bevilacqua MP. An inducible endothelial cell surface glycoprotein
mediates melanoma adhesion. Science. 1989;246(4935):1303–6.
16. Castrechini NM, Murthi P, Gude NM, Erwich JJ, Gronthos S, Zannettino A, et al.
Mesenchymal stem cells in human placental chorionic villi reside in a vascular
Niche. Placenta. 2010;31(3):203–12. doi:10.1016/j.placenta.2009.12.006.
17. Kwee L, Baldwin HS, Shen HM, Stewart CL, Buck C, Buck CA, et al. Defective
development of the embryonic and extraembryonic circulatory systems in
vascular cell adhesion molecule (VCAM-1) deficient mice. Development.
1995;121(2):489–503.
18. Koch AE, Halloran MM, Haskell CJ, Shah MR, Polverini PJ. Angiogenesis
mediated by soluble forms of E-selectin and vascular cell adhesion
molecule-1. Nature. 1995;376(6540):517–9. doi:10.1038/376517a0.
19. Vanderslice P, Munsch CL, Rachal E, Erichsen D, Sughrue KM, Truong AN,
et al. Angiogenesis induced by tumor necrosis factor-agr; is mediated by
alpha4 integrins. Angiogenesis. 1998;2(3):265–75.
20. Ding YB, Chen GY, Xia JG, Zang XW, Yang HY, Yang L. Association of VCAM-
1 overexpression with oncogenesis, tumor angiogenesis and metastasis of
gastric carcinoma. World J Gastroenterol. 2003;9(7):1409–14.
21. Byrne GJ, Ghellal A, Iddon J, Blann AD, Venizelos V, Kumar S, et al. Serum
soluble vascular cell adhesion molecule-1: role as a surrogate marker of
angiogenesis. J Natl Cancer Inst. 2000;92(16):1329–36.
22. Hemmerlein B, Scherbening J, Kugler A, Radzun HJ. Expression of VCAM-1,
ICAM-1, E- and P-selectin and tumour-associated macrophages in renal cell
carcinoma. Histopathology. 2000;37(1):78–83.
23. Yang ZX, Han ZB, Ji YR, Wang YW, Liang L, Chi Y, et al. CD106
identifies a subpopulation of mesenchymal stem cells with unique
immunomodulatory properties. PLoS One. 2013;8(3):e59354.
doi:10.1371/journal.pone.0059354.
24. Zhou B, Bi YY, Han ZB, Ren H, Fang ZH, Yu XF, et al. G-CSF-mobilized
peripheral blood mononuclear cells from diabetic patients augment
neovascularization in ischemic limbs but with impaired capability. J Thromb
Haemost. 2006;4(5):993–1002. doi:10.1111/j.1538-7836.2006.01906.x.
25. Malinda KM. In vivo matrigel migration and angiogenesis assay. Methods
Mol Biol. 2009;467:287–94. doi:10.1007/978-1-59745-241-0_17.
26. Bian S, Zhang L, Duan L, Wang X, Min Y, Yu H. Extracellular vesicles derived
from human bone marrow mesenchymal stem cells promote angiogenesis in
a rat myocardial infarction model. J Mol Med (Berl). 2014;92(4):387–97. doi:10.
1007/s00109-013-1110-5.
27. Zhang HC, Liu XB, Huang S, Bi XY, Wang HX, Xie LX, et al. Microvesicles
derived from human umbilical cord mesenchymal stem cells stimulated by
hypoxia promote angiogenesis both in vitro and in vivo. Stem Cells Dev.
2012;21(18):3289–97. doi:10.1089/scd.2012.0095.
28. Liang X, Ding Y, Zhang Y, Tse HF, Lian Q. Paracrine mechanisms of
mesenchymal stem cell-based therapy: current status and perspectives. Cell
Transplant. 2014;23(9):1045–59. doi:10.3727/096368913X667709.
Du et al. Stem Cell Research & Therapy  (2016) 7:49 Page 12 of 13
29. Gnecchi M, He H, Noiseux N, Liang OD, Zhang L, Morello F, et al. Evidence
supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-
mediated cardiac protection and functional improvement. FASEB J.
2006;20(6):661–9. doi:10.1096/fj.05-5211com.
30. Suga H, Glotzbach JP, Sorkin M, Longaker MT, Gurtner GC. Paracrine
mechanism of angiogenesis in adipose-derived stem cell
transplantation. Ann Plast Surg. 2014;72(2):234–41. doi:10.1097/SAP.
0b013e318264fd6a.
31. Yao Y, Huang J, Geng Y, Qian H, Wang F, Liu X, et al. Paracrine action of
mesenchymal stem cells revealed by single cell gene profiling in infarcted
murine hearts. PLoS One. 2015;10(6):e0129164. doi:10.1371/journal.pone.0129164.
32. Bussolino F, Di Renzo MF, Ziche M, Bocchietto E, Olivero M, Naldini L, et al.
Hepatocyte growth factor is a potent angiogenic factor which stimulates
endothelial cell motility and growth. J Cell Biol. 1992;119(3):629–41.
33. Li A, Varney ML, Valasek J, Godfrey M, Dave BJ, Singh RK. Autocrine role of
interleukin-8 in induction of endothelial cell proliferation, survival, migration
and MMP-2 production and angiogenesis. Angiogenesis. 2005;8(1):63–71.
doi:10.1007/s10456-005-5208-4.
34. Wiedlocha A. Following angiogenin during angiogenesis: a journey from
the cell surface to the nucleolus. Arch Immunol Ther Exp (Warsz).
1999;47(5):299–305.
35. Asahara T, Chen D, Takahashi T, Fujikawa K, Kearney M, Magner M, et al.
Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate
VEGF-induced postnatal neovascularization. Circ Res. 1998;83(3):233–40.
36. Wang D, Wang H, Brown J, Daikoku T, Ning W, Shi Q, et al. CXCL1 induced
by prostaglandin E2 promotes angiogenesis in colorectal cancer. J Exp Med.
2006;203(4):941–51. doi:10.1084/jem.20052124.
37. Del Rosso M. uPAR in angiogenesis regulation. Blood. 2011;117(15):3941–3.
doi:10.1182/blood-2011-02-337733.
38. Sola-Villa D, Camacho M, Sola R, Soler M, Diaz JM, Vila L. IL-1beta induces
VEGF, independently of PGE2 induction, mainly through the PI3-K/mTOR
pathway in renal mesangial cells. Kidney Int. 2006;70(11):1935–41.
doi:10.1038/sj.ki.5001948.
39. Salven P, Hattori K, Heissig B, Rafii S. Interleukin-1alpha promotes angiogenesis
in vivo via VEGFR-2 pathway by inducing inflammatory cell VEGF synthesis and
secretion. FASEB J. 2002;16(11):1471–3. doi:10.1096/fj.02-0134fje.
40. Zhao J, Chen L, Shu B, Tang J, Zhang L, Xie J, et al. Granulocyte/macrophage
colony-stimulating factor influences angiogenesis by regulating the coordinated
expression of VEGF and the Ang/Tie system. PLoS One. 2014;9(3):e92691.
doi:10.1371/journal.pone.0092691.
41. Shojaei F, Wu X, Qu X, Kowanetz M, Yu L, Tan M, et al. G-CSF-initiated
myeloid cell mobilization and angiogenesis mediate tumor refractoriness to
anti-VEGF therapy in mouse models. Proc Natl Acad Sci U S A. 2009;106(16):
6742–7. doi:10.1073/pnas.0902280106.
42. Bousquenaud M, Schwartz C, Leonard F, Rolland-Turner M, Wagner D, Devaux
Y. Monocyte chemotactic protein 3 is a homing factor for circulating
angiogenic cells. Cardiovasc Res. 2012;94(3):519–25. doi:10.1093/cvr/cvs140.
43. Inokuma D, Abe R, Fujita Y, Sasaki M, Shibaki A, Nakamura H, et al. CTACK/
CCL27 accelerates skin regeneration via accumulation of bone marrow-
derived keratinocytes. Stem Cells. 2006;24(12):2810–6. doi:10.1634/
stemcells.2006-0264.
44. Benslimane-Ahmim Z, Heymann D, Dizier B, Lokajczyk A, Brion R, Laurendeau I,
et al. Osteoprotegerin, a new actor in vasculogenesis, stimulates endothelial
colony-forming cells properties. J Thromb Haemost. 2011;9(4):834–43.
doi:10.1111/j.1538-7836.2011.04207.x.
45. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D,
et al. Minimal criteria for defining multipotent mesenchymal stromal cells.
The International Society for Cellular Therapy position statement.
Cytotherapy. 2006;8(4):315–7. doi:10.1080/14653240600855905.
46. Hsiao ST, Asgari A, Lokmic Z, Sinclair R, Dusting GJ, Lim SY, et al. Comparative
analysis of paracrine factor expression in human adult mesenchymal stem cells
derived from bone marrow, adipose, and dermal tissue. Stem Cells Dev.
2012;21(12):2189–203. doi:10.1089/scd.2011.0674.
47. Peltzer J, Montespan F, Thepenier C, Boutin L, Uzan G, Rouas-Freiss N, et al.
Heterogeneous functions of perinatal mesenchymal stromal cells require a
preselection before their banking for clinical use. Stem Cells Dev. 2015;24(3):
329–44. doi:10.1089/scd.2014.0327.
48. Psaltis PJ, Paton S, See F, Arthur A, Martin S, Itescu S, et al. Enrichment for
STRO-1 expression enhances the cardiovascular paracrine activity of human
bone marrow-derived mesenchymal cell populations. J Cell Physiol. 2010;
223(2):530–40. doi:10.1002/jcp.22081.
49. Gronthos S, Zannettino AC, Hay SJ, Shi S, Graves SE, Kortesidis A, et al.
Molecular and cellular characterisation of highly purified stromal stem cells
derived from human bone marrow. J Cell Sci. 2003;116(Pt 9):1827–35.
50. Wang CM, Guo Z, Xie YJ, Hao YY, Sun JM, Gu J, et al. Co-treating
mesenchymal stem cells with IL1beta and TNF-alpha increases VCAM-1
expression and improves post-ischemic myocardial function. Mol Med Rep.
2014;10(2):792–8. doi:10.3892/mmr.2014.2236.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Du et al. Stem Cell Research & Therapy  (2016) 7:49 Page 13 of 13
